echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Mm classic drug: lainadu amine is the best in the world

    Mm classic drug: lainadu amine is the best in the world

    • Last Update: 2019-07-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On 5th of this month, nmpa approved the import registration application of daratumab injection, a Johnson & Johnson heavyweight product, for the single drug treatment of relapsed and refractory multiple myeloma (mm) adult patients, including those who had previously received a proteasome inhibitor and an immunomodulator and had disease progression during the last treatment The choice of medication for MM patients in China has been enriched again Let's look at the classic medication and market analysis of MM summarized by the author Multiple myeloma (mm) is a kind of malignant tumor with abnormal proliferation of plasma cells in the bone marrow, also known as plasmacytoma (Figure 1) It occurs in the middle-aged and elderly (> 40 years old), with occult onset, often accompanied by multiple osteolytic damage, hypercalcemia, anemia, kidney damage and other clinical symptoms (Table 1) Therefore, many patients go to the Department of Endocrinology, Nephrology, orthopedics and so on, Causes misdiagnosis and missed diagnosis of the disease With the aging of China's population, the incidence rate of myeloma is increasing year by year At present, mm has surpassed leukemia and become the second most lethal hematological malignancy Chart 1MM's pathogenesis principle 1MM clinical symptoms CRAB MM classical medicine and market analysis 1, MM target drugs are various, and the amine / zomib drugs are the first choice because plasma cells are differentiated from B lymphocytes, MM also belongs to B cell lymphoma, the incidence rate of MM in Europe and America is significantly higher than that in China, and there are 9 kinds of drugs listed on the list (2) only NCCN recommends Among them, two kinds of new drugs: immunomodulators, diamines and proteasome inhibitors, Zomi, are the two preferred drugs for mm The combination of the two drugs is expected to become the standard therapy, greatly improving the remission rate of mm Table 2: the list of classic drugs of 2mm: enl (erythema nodosum), MCL (lymphoma), MDS (multiple sclerosis), CLL (chronic lymphoid leukemia), auto HSCT (autologous hematopoietic stem cell transplantation) 2 The best protease inhibitors: bortezomib, Qilu pharmaceutical qipule to relieve the drug price pressure Figure 2 sales volume of zombie drugs (million US dollars) bortezomib is the first proteasome inhibitor, which has the advantages of quick onset, high safety, small stem cell damage, etc in NCCN guide 2018, five combination drug schemes are recommended for induction treatment of MM primary patients, bortezomib is the main drug of four schemes In 2014, its global sales reached US $3 billion (Figure 2), and it has been listed in the top 10 list of global anti-tumor brand drug sales for several consecutive years Domestic bortezomib (qipule) of Qilu pharmaceutical was listed in China in 2018, and the price is two-thirds of the payment standard of the national medical insurance negotiation of the original research product, which can significantly alleviate the pressure of the high cost of the original research and import bortezomib, and increase the availability of drugs 3 Leader in immunomodulators: lenalidomide, also the world's leading anti-tumor drug Figure 3, the sales volume of amines (million US dollars), however, the ups and downs of the market should be attributed to thalidomide, from the fad to the stop of reaction, to the coming out of the market.. But the side effects still limit its clinical use, and the sales volume has not been broken through (Figure 3) But on this basis, through the chemical structure modification, the second generation of immunomodulator lenalidomide was created, which is also the only drug recommended by NCCN guidelines for maintenance treatment Since its launch in 2006, the sales of lenalidomide has maintained a steady growth momentum In 2017 and 2018, the sales of lenalidomide reached 8.187 billion and 9.685 billion US dollars, respectively With an absolute advantage of about 2 billion US dollars, lenalidomide is ahead of the top 2 drug, odivo, and ranks first in the world in terms of anti-tumor drugs (Figure 4) It is estimated that the global annual sales of lenalidomide will reach up to 10 billion US dollars in 2020! Figure 4 sales of lenalidomide ranked first in the world in terms of anti-tumor drugs 4 The domestic market of lenalidomide is bleak and bleak, and the domestic generic drugs with the price close to the people are in the top position in the world in terms of anti-tumor drugs Lenalidomide is well-known, but the domestic market is generally bleak, mainly limited by its high price and the limitations of the types of domestic medical insurance reimbursement drugs In 2013, lenalidomide was introduced into China, and finally included in the national B-type medical insurance in 2017 However, each drug of 25mg is still more than 1000 yuan Although the price of some anti-cancer drugs has been adjusted subsequently, the drug cost of patients in a year will also be several hundred thousand yuan The listing of domestic generic drugs is the right solution! The domestic Shuanglu pharmaceutical industry has been on the market for two years In February this year, the sales price of lison, a generic drug of nanduramine, dropped from 20000 yuan to 3000-6000 yuan Meanwhile, as the second domestic generic drug, Anxian, Zhengda Tianqing, also went on the market at 5380 yuan / box Cheap and affordable domestic generic drugs can really benefit MM patients Jiangsu Haosen Pharmaceutical Co., Ltd., Yangzijiang Pharmaceutical Co., Ltd and Qilu Pharmaceutical Co., Ltd are also laying out lenalidomide generic drugs In the future, the listing of these domestic generic drugs and the inclusion of medical insurance, the price of lenalidomide is bound to continue to decline, reduce the drug burden of patients, and truly benefit MM patients Reference materials: public information, insight, FDA, NEJM, medicine magic cube, Shenwan Hongyuan research, etc This article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.